202 related articles for article (PubMed ID: 27320114)
1. [Incidence and Risk Assessment of Tumor Lysis Syndrome in Patients with Advanced Germ Cell Cancer].
Kurobe M; Kawai K; Tanaka K; Ichioka D; Yoshino T; Kandori S; Kawahara T; Waku N; Takaoka E; Kojima T; Joraku A; Suetomi T; Miyazaki J; Nishiyama H
Hinyokika Kiyo; 2016 May; 62(5):237-42. PubMed ID: 27320114
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
Cairo MS; Coiffier B; Reiter A; Younes A;
Br J Haematol; 2010 May; 149(4):578-86. PubMed ID: 20331465
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases.
Pentheroudakis G; O'Neill VJ; Vasey P; Kaye SB
Support Care Cancer; 2001 Oct; 9(7):554-7. PubMed ID: 11680837
[TBL] [Abstract][Full Text] [Related]
5. [Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
Kobayashi S; Yasu T; Sato K; Ohno N; Kuroda S
Gan To Kagaku Ryoho; 2018 May; 45(5):879-881. PubMed ID: 30026457
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
8. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
9. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
10. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
[TBL] [Abstract][Full Text] [Related]
11. Tumour lysis syndrome in children: experience of last decade.
Ahn YH; Kang HJ; Shin HY; Ahn HS; Choi Y; Kang HG
Hematol Oncol; 2011 Dec; 29(4):196-201. PubMed ID: 21710502
[TBL] [Abstract][Full Text] [Related]
12. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
13. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Ribeiro RC; Pui CH
Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
[TBL] [Abstract][Full Text] [Related]
14. Clarifying the role of rasburicase in tumor lysis syndrome.
Sood AR; Burry LD; Cheng DK
Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
[TBL] [Abstract][Full Text] [Related]
15. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
Baeksgaard L; Sørensen JB
Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
[TBL] [Abstract][Full Text] [Related]
16. Rasburicase for the management of tumor lysis syndrome in neonates.
McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
[TBL] [Abstract][Full Text] [Related]
17. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
Holdsworth MT; Nguyen P
Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
[TBL] [Abstract][Full Text] [Related]
18. Management of tumor lysis syndrome in adults.
Coiffier B; Riouffol C
Expert Rev Anticancer Ther; 2007 Feb; 7(2):233-9. PubMed ID: 17288532
[TBL] [Abstract][Full Text] [Related]
19. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Bessmertny O; Robitaille LM; Cairo MS
Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
[TBL] [Abstract][Full Text] [Related]
20. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Bose P; Qubaiah O
J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]